From preclinical research to regulatory approval and clinical adoption, diagnostic testing underpins every stage of ADC ...

By targeting surface markers on cancer cells, engineered synthetic receptors expressed on immune cells can be directed to ...

The inhaled monoclonal antibody IN-006 shows promise in COVID-19 treatment, with high airway antibody levels and a favorable safety profile in healthy adults.

Antibody design to improve homogeneity and potential for development. Antibodies are a successful class of therapeutic agents, but many treaments remain costly, which may limit their use ...

Targeted Oncology provides news, videos, and reviews on the rapidly evolving world of targeted therapies and immunotherapy ...

Bolt Biotherapeutics, Inc., announced today that the target of their worldwide co-development collaboration with Toray Industries, Inc. is Caprin-1, a novel cancer target discovered by Toray. The ...

Crispr Therapeutics AG has revenue declines but holds strong financials. Promising Sickle Cell therapy & 2025 data readouts ...

About Abelacimab Abelacimab is a novel, investigational, highly selective, fully human monoclonal antibody that binds tightly to Factor XI to block its activation and prevent the generation of the ...

The table below is a review of notable updates that occurred in January 2025 for investigational products in development.

As part of the funding, Latent Labs aims to leverage generative artificial intelligence to computationally create novel ...